Organogenesis Q2 revenue down 58% to $42.8M; net loss widens to $96.3M; FY guidance slashed

Organogenesis Holdings Inc.

Net revenue $42.8M vs $100.8M YoY; Advanced Wound Care fell 61% to $36.1M.
Net loss $96.3M ($0.77/share) vs $9.4M loss ($0.10/share) in Q2 2025.
Adjusted EBITDA loss $34.4M vs $3.6M loss; operating loss $51.0M vs $12.6M.
FY 2026 revenue guidance cut to $179M-$215M (62-68% decline) from prior 45-52% decline.
Cash $46.8M, no debt; CEO cites slower-than-expected market recovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.